LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Zai Lab Ltd ADR

Avatud

SektorTervishoid

31.42 0.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

30.97

Max

31.65

Põhinäitajad

By Trading Economics

Sissetulek

7.7M

-41M

Müük

3.5M

110M

Kasumimarginaal

-37.032

Töötajad

1,869

EBITDA

1.4M

-55M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+80.75% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-478M

3.7B

Eelmine avamishind

31.23

Eelmine sulgemishind

31.42

Uudiste sentiment

By Acuity

100%

0%

360 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2025, 23:59 UTC

Omandamised, ülevõtmised, äriostud

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. sept 2025, 22:02 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Tron Shares Rise After New Investment From Bravemorning

8. sept 2025, 16:14 UTC

Suurimad hinnamuutused turgudel

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. sept 2025, 16:13 UTC

Suurimad hinnamuutused turgudel

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. sept 2025, 21:47 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4B AI Deal With Nebius

8. sept 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. sept 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. sept 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. sept 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. sept 2025, 16:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 16:16 UTC

Tulu

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

80.75% tõus

12 kuu keskmine prognoos

Keskmine 56.63 USD  80.75%

Kõrge 74 USD

Madal 39 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat